Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtFool - Investing News · 4 days ago
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term CatalystSeeking Alpha · Oct 15, 2026
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street AnalystsDefense World · Sep 28, 2026
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewsWire · Sep 2, 2026
Scribe Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 1, 2026
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More247 Wallst · Aug 31, 2026Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 2, 2026 | -$3.62 | -$2.62 | Beat |